Evaluation of CRP SNV rs2808630 and acute proinflammatory biomarkers in patients with CKD and PLHIV with CKD: a case-control study

Table 2 Comparisons of genotype and allelic frequencies between controls, CKD patients and PLHIV with CKD

Genotype/ Allele	Group	Frequency, n (%)	Comparison	OR	95% CI	p
TT	Control	67 (59.4%)	Control vs. CKD	0.9430	0.5764 to 1.552	0.8979^a
	CKD	90 (61.2%)	Control vs. PLHIV with CKD	0.8017	0.4654 to 1.409	0.4794^a
	PLHIV with CKD	65 (65%)	CKD vs. PLHIV with CKD	0.8502	0.5049 to 1.454	0.5929^a
TC	Control	40 (36%)	Control vs. CKD	0.9293	0.5531 to 1.540	0.7960^a
	CKD	55 (37.4%)	Control vs. PLHIV with CKD	1.181	0.6541 to 2.070	0.6632^a
	PLHIV with CKD	32 (32%)	CKD vs. PLHIV with CKD	1.270	0.7322 to 2.187	0.4172^a
CC	Control	5 (4.5%)	Control vs. CKD	0.2952	0.0580 to 1.414	0.2447^a
	CKD	2 (1.3%)	Control vs. PLHIV with CKD	0.6619	0.1719 to 2.590	0.7249^a
	PLHIV with CKD	3 (3%)	CKD vs. PLHIV with CKD	2.242	0.4495 to 12.78	0.3971^a
T (Allele)	Control	172 (77.4%)	Control vs. CKD	0.8637	0.5666 to 1.329	0.5149^a
	CKD	235 (79.9%)	Control vs. PLHIV with CKD	0.8069	0.4987 to 1.280	0.4023^a
	PLHIV with CKD	162 (81%)	CKD vs. PLHIV with CKD	0.9343	0.5974 to 1.459	0.8180^a
C (Allele)	Control	50 (22.5%)	Control vs. CKD	1.158	0.7524 to 1.765	0.5149^a
	CKD	59 (20%)	Control vs. PLHIV with CKD	1.239	0.7815 to 2.005	0.4023^a
	PLHIV with CKD	38 (19%)	CKD vs. PLHIV with CKD	1.070	0.6852 to 1.674	0.8180^a

PLHIV: People Living with HIV, CKD: Chronic Kidney Disease, CI: Confidence Interval. Qualitative variables expressed as frequencies and percentages. ^a: Chi square

ISSN: 1471-2369